Alpha Cognition (Alpha Cognition) Net Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Alpha Cognition's Net Income for the three months ended in Mar. 2024 was $-5.00 Mil. Alpha Cognition's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Alpha Cognition's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Alpha Cognition's Net Margin % or its related term are showing as below:

ACOGF's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.41
* Ranked among companies with meaningful Net Margin % only.

Alpha Cognition Net Margin % Historical Data

The historical data trend for Alpha Cognition's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Net Margin % Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Alpha Cognition's Net Margin %

For the Biotechnology subindustry, Alpha Cognition's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Cognition's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's Net Margin % distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's Net Margin % falls into.

Alpha Cognition Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Alpha Cognition's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-13.773	/	0
	=	%

Alpha Cognition's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-4.999	/	0
	=	%

Alpha Cognition (OTCPK:ACOGF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Alpha Cognition Net Margin % Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (Alpha Cognition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

ACOG:Canada

Address

301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2

Website

https://www.alphacognition.com

Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.